PHM12 COST-EFFECTIVENESS OF DASATINIBVS IMATINIB 800 MG/ DAY IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN  by Brosa, M et al.
various elective knee surgeries with rFVIIa coverage in hemo-
philiacs with inhibitors from a US payer perspective.
METHODS: A literature-based Markov model was used to
compare the direct medical costs and quality-adjusted life-years
(QALYs) of 2 hypothetical cohorts of hemophiliacs with inhibi-
tors and frequent bleeding episodes: one undergoing elective
orthopedic surgery and the other not undergoing surgery. Based
on the published literature, surgery was assumed to reduce bleed-
ing frequency by 82%, from 9.13 to 1.64 episodes per year, and
improve pain and quality of life. Surgery costs included periop-
erative rFVIIa costs, inpatient and rehabilitation care, and repeat
procedures. RESULTS: Estimated knee surgery costs ranged from
$677,000 (in knee arthrodesis [KA]) to $840,000 (in total knee
replacement [TKR]). Surgery reduced the incidence of bleeding
episodes and resultant costs. Speciﬁcally, the cumulative dis-
counted savings in bleeding-related costs were $537,000 and
$991,000 at 5 and 10 years, respectively. Overall, the cost of
surgery was offset within 7 to 9 years of the index procedure,
depending on the surgery. Surgery also resulted in discounted net
gains of 1.88 and 3.47 QALYs after 5 and 10 years, respectively.
The cost per QALY gained with KA and TKR fell under $50,000
during the 6th and 7th years, respectively. Changes in assump-
tions regarding prophylaxis regimen, survival, baseline bleeding
frequency, patient weight, and rate of repeat surgery affected the
results to various degrees. CONCLUSION: Despite high upfront
costs, knee surgery with rFVIIa in hemophiliacs with inhibitors
leads to cost savings and QALY gains within a few years, prima-
rily due to reductions in bleeding episodes.
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OBJECTIVES: The cost-effectiveness of dasatinib was evaluated,
comparing dasatinib (2 ¥ 70 mg) to 800 mg imatinib per day in
imatinib-resistant chronic CML, from the perspective of the
Spanish health care system. METHODS: A Markov model was
developed (cycle length one month) which incorporates clinical,
epidemiological and cost data to assess the cost-effectiveness of
dasatinib compared to imatinib in imatinib-resistant chronic
CML patients (95% of CML patients in Spain). The model
allows the simulation of the distribution of patients over the
chronic, accelerated and blast phase of CML. At model entry,
patients are classiﬁed according to initial best response rates,
from randomised Phase II clinical trial data comparing dasatinib
with imatinib (800 mg) in imatinib resistant patients. Distinction
is made between no response, complete hematological response,
partial cytogenetic response and complete cytogenetic response.
Disease progression depends on initial response to treatment.
Treatment costs were obtained from eSalud, a health care cost
database in Spain. Health effects and costs were counted until all
patients reached the “death” state. Both costs and effects were
discounted annually at 3.5%. The robustness of the results was
tested in deterministic sensitivity analyses. RESULTS: In the base
case analysis, treatment with dasatinib is associated with a gain
of 0.64 quality adjusted life-years (QALY) and cost savings of
€16,600, resulting in an estimate of dominance for dasatinib.
Sensitivity analysis of key variables conﬁrmed that results remain
located in the south-east quadrant of the CE-plane (i.e. domi-
nance). CONCLUSION: Compared to imatinib, dasatinib is
associated with increased life expectancy and lower overall costs,
indicating that dasatinib is a dominant treatment strategy for the
treatment of patients with CML who are resistant to imatinib.
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OBJECTIVES: In 2004 the German government limited the
adoption of assisted reproductive technology (ART) treatment
costs by statutory health insurance from 100 to 50 percent.
Furthermore age limits were adapted and the number of funded
ART cycles was restricted from four to three cycles. The aim of
this study was to estimate the effect of restricting fertility services
from a health fund’s perspective. METHODS: Over the period of
2002 to 2005 our study investigated the changes in the number
of ART cycles, treatment costs and birth rates after assisted
reproduction. The analysis is based on health insurance fre-
quency statistics including fee schedule items reimbursed by
health insurance funds. ART cycles included intrauterine insemi-
nation (in natural or stimulated cycles), in vitro fertilisation and
intracytoplasmic sperm injection. RESULTS: The number of
funded ART cycles ranged from 73,405 in 2002, 104,542 in
2003, 35,352 in 2004 to 32,099 in 2005. The number of ART
cycles increased expectedly between 2002 and 2003. The gain
add up to 42%. In 2004 the number of ART cycles decreased by
66%. This downward trend continued in 2005 with a decline by
another 9%. In 2004 treatment costs funded by the health insur-
ance decreased by 84% according to the limitation of reimburse-
ment. Corresponding to the falling number of ART cycles the
birth rate depending on ART decreased too. However, the
decrease had no statistically signiﬁcant impact on the common
birth rate in Germany. CONCLUSION: With restricting fertility
services the number of ART cycles declined statistically. The
absolute number of births decreased too. One of the reasons may
be high co-payments which will mean many patients can not
longer afford this special kind of medical treatment.
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OBJECTIVES: To ﬁnd evidence on the economic impact of
anemia and transfusion in MDS and estimate the prevalence
of transfusion-dependent MDS patients in Germany and make
a ﬁrst appraisal of the economic impact of these patients.
METHODS: Literature search via PUBMED was systematically
conducted (covering January 1996 to December 2006) using
deﬁned search terms, e.g. Myelodysplastic Syndrome AND
Transfusion AND Cost and cost analysis OR cost of illness. From
the German transfusion medicine’s perspective desk-top
researches were conducted to evaluate the economic burden of
transfusion-dependency of MDS patients in Germany. RESULTS:
Three cost-analyses regarding transfusion costs of MDS patients
were identiﬁed with major distinctions in study design, methods,
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